(PRWEB) December 28, 2012
Law Firm Offers No Win - No Fee Promise For Clients injured from the drug Fosamax, used to treat bone-weakening diseases. Fosamax has allegedly been linked to serious side effects, such as femur fractures, osteonecrosis of the jaw injury, esophageal cancer, and severe musculoskeletal pain.
The personal injury lawyers at d'Oliveira & Associates are working with some of the leading lawyers in the country and are seeking currently clients who have suffered from femur fractures, osteonecrosis of the jaw injury, esophageal cancer, and severe musculoskeletal pain while using Fosamax. They are offering a “no win - no fee promise” to those who took Fosamax, which means that there is no legal fees due until the case is settled or an award is received.
Recent news shows promise that the lawsuits are moving forward for the plaintiffs who have filed lawsuits against Fosamax. New Jersey Superior Court has scheduled the next status conference on the consolidated Fosamax litigation for December 18, 2012 at 10:00am. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct). Additionally, femur fracture lawsuits against Fosamax are pending in a multidistrict litigation (MDL) in the U.S. District Court in the District of New Jersey. (In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II) - MDL No. 2243). According to state records, the first trials against Fosamax in both state and federal courts are expected to begin next spring.
A study published in October 2012 by the Journal of Clinical Endocrinology & Metabolism indicates that patients suffering from atypical femur fractures also experienced delayed healing, prodromal pain (pain experienced prior to the actual fracture), and persisting risk of a contralateral and/or other fracture. In this study, the author analyzed 81 patients who had suffered atypical femur fractures while taking biphosphonates, the generic name for Fosamax, for treatment of osteoporosis for an average of 9.5 years, and 94% of these patients have been taken Fosamax. Another study of more than 300 cases conducted by the American Society of Bone and Mineral Research Subtrochanteric Femoral Fracture Task Force found that most of those that suffered fractures had been on the drug for five years or more. They also found that more than half of the patients studied had experience groin or thigh pain for a period of weeks or months before their fractures occurred.
As a result of these studies, the U.S. Food and Drug Administration issued a warning about Fosamax. The FDA mandated that the drug manufacturer include information in its Warnings and Precautions section of the drug labels about the possible associations between the atypical thigh fractures and the Fosamax. FDA mentioned that although these types of fractures account for only 1% of all hip and femur fractures overall, they have been predominantly reported by patients who have been taking Fosamax for at least 5 years.
Attorney Paul d’Oliveira stated that “our office is doing all we can to let the public know that if they have been injured by Fosamax that they can be compensated for their injuries at no cost to them until their case settles or until they receive a monetary reward.”
To help protect the rights of individuals who may have suffered injuries such as femur fractures, osteonecrosis of the jaw injury, esophageal cancer, and severe musculoskeletal pain while using Fosamax, d'Oliveira & Associates is offering a No Win - No Fee Promise. Those who choose to hire d'Oliveira & Associates will be charged no fee unless they recover monetary damages, such as through a settlement or judgment.
d’Oliveira and Associates is a law firm that is working with some of the leading attorneys in the United States for dangerous drug, defective medical products and medical malpractice cases. The firm also focuses on personal injury cases, including auto accidents, slip and falls, dog bites, as well as social security disability cases.
For a free consultation, call 1-800-992-6878 or visit their website at Fosamax Lawyer
Read the full story at http://www.prweb.com/releases/2012/12/prweb10270800.htm.
Copyright©2012 Vocus, Inc.
All rights reserved